397 related articles for article (PubMed ID: 30115750)
1. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
[TBL] [Abstract][Full Text] [Related]
2. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
3. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
4. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
[TBL] [Abstract][Full Text] [Related]
5. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
8. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
[TBL] [Abstract][Full Text] [Related]
9. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
[TBL] [Abstract][Full Text] [Related]
11.
Atas-Ozcan H; Brault V; Duchon A; Herault Y
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828439
[TBL] [Abstract][Full Text] [Related]
12. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
[TBL] [Abstract][Full Text] [Related]
13. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
14. cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.
Fant X; Durieu E; Chicanne G; Payrastre B; Sbrissa D; Shisheva A; Limanton E; Carreaux F; Bazureau JP; Meijer L
Mol Pharmacol; 2014 Mar; 85(3):441-50. PubMed ID: 24366666
[TBL] [Abstract][Full Text] [Related]
15. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
Marechal D; Brault V; Leon A; Martin D; Lopes Pereira P; Loaëc N; Birling MC; Friocourt G; Blondel M; Herault Y
Hum Mol Genet; 2019 May; 28(9):1561-1577. PubMed ID: 30649339
[TBL] [Abstract][Full Text] [Related]
16. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
Becker W; Soppa U; Tejedor FJ
CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
[TBL] [Abstract][Full Text] [Related]
17. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Tahtouh T; Elkins JM; Filippakopoulos P; Soundararajan M; Burgy G; Durieu E; Cochet C; Schmid RS; Lo DC; Delhommel F; Oberholzer AE; Pearl LH; Carreaux F; Bazureau JP; Knapp S; Meijer L
J Med Chem; 2012 Nov; 55(21):9312-30. PubMed ID: 22998443
[TBL] [Abstract][Full Text] [Related]
18. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
[TBL] [Abstract][Full Text] [Related]
19. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]